High on-treatment platelet reactivity in peripheral endovascular procedures

CardioVascular and Interventional Radiology

Volumn 37, Issue 3, 2014, Pages 559-571

  Spiliopoulos, Stavros ^a   Kassimis, George ^b   Hatzidakis, Adam ^c   Krokidis, Miltiadis ^d  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Arterial intervention; Arteriosclerosis; Endovascular treatment; Peripheral vascular; Peripheral vascular disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; PRASUGREL; STREPTOKINASE; TICAGRELOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGE; BLEEDING TIME; BODY MASS; CORONARY ARTERY BYPASS SURGERY; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG TRANSFORMATION; ENDOVASCULAR SURGERY; FOLLOW UP; GENETIC VARIABILITY; GOLD STANDARD; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PERIPHERAL ENDOVASCULAR PROCEDURE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RICH PLASMA; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; DRUG EFFECTS; PERIPHERAL ARTERIAL DISEASE; THROMBOCYTE;

ASPIRIN; ATHEROSCLEROSIS; BLOOD PLATELETS; ENDOVASCULAR PROCEDURES; HUMANS; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84901652830     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-013-0707-y     Document Type: Review

References (125)

1. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E et al (1996) Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 25:1172-1181 (Pubitemid 27013522)
2. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ et al (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381-386
3. Perk J, DeBacker G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al., European Association for Cardiovascular Prevention and Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG) (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 33:1635-1701
4. Hussein AA, Uno K, Wolski K, Kapadia S, Schoenhagen P, Tuzcu EM, Nissen SE et al (2011) Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol 57:1220-1225
5. Narins CR, Zareba W, Moss AJ, Marder VJ, Ridker PM, Krone RJ et al (2004) Relationship between intermittent claudication, inflammation, thrombosis and recurrent cardiac events among survivors of myocardial infarction. Arch Intern Med 164: 440-446 (Pubitemid 38240709)
6. Newman AB, Shemanski L, Manolio TA, Cushman M, Mittelmark M, Polak JF et al (1999) Ankle-arm index as a predictor of cardiovascular disease and mortality in the cardiovascular health study. Arterioscler Thromb Vasc Biol 19:538-545 (Pubitemid 29135153)
7. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Röther J, REACH Registry Investigators et al (2007) One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297:1197-1206 (Pubitemid 46465728)
8. Organisation EuropeanStroke, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, ESC Committee for Practice Guidelines et al (2011) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC), endorsed by: The European Stroke Organisation (ESO). Eur Heart J 32:2851-2906
9. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
10. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324:71-86
11. Mazur P, Frołow M, Niżankowski R, Sadowski J, Undas A (2013) Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. Platelets 24(2): 151-155
12. Linnemann B, Thalhammer A, Wolf Z, Tirneci V, Vogl TJ, Edelgard Lindhoff-Last A (2012) Late peripheral stent thrombosis due to stent fracture, vigorous exercise and hyporesponsiveness to clopidogrel. Vasa 41:136-144
13. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators et al (2008) Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 118: 1705-1712
14. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002) Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105:1650-1655 (Pubitemid 34298607)
15. Madsen EH, Gehr NR, Johannesen NL, Schmidt EB, Kristensen SR (2011) Platelet response to aspirin and clopidogrel in patients with peripheral atherosclerosis. Platelets 22:537-546
16. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D et al (2007) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003-1007
17. Ziegler S, Maca T, Alt E, Speiser W, Schneider B, Minar E (2002) Monitoring of antiplatelet therapy with the PFA-100 in peripheral angioplasty patients. Platelets 13:493-497 (Pubitemid 35373664)
18. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754-762
19. Fifi JT, Brockington C, Narang J, Leesch W, Ewing SL, Bennet H et al (2013) Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. Am J Neuroradiol 34:716-720
20. Reavey-Cantwell JF, Fox WC, Fautheree GL, Velat GJ, Whiting JH, Chi YY et al (2009) Factors associated with aspirin resistance in patients premedicated with aspirin and clopidogrel for endovascular neurosurgery. Neurosurgery 64:890-895
21. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK (2008) Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. Am J Neuroradiol 29:281-285 (Pubitemid 351287881)
22. Müller-Schunk S, Linn J, Peters N, Spannagl M, Deisenberg M, Brückmann H et al (2008) Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. Am J Neuroradiol 29:786-791 (Pubitemid 351571565)
23. Rho GJ, Shin WR, Kong TS, Kim MS, Lee CJ, Lee BH (2011) Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. J Korean Neurosurg Soc 50:40-44
24. Saunders J, Nambi V, Kimball KT, Virani SS, Morrisett JD, Lumsden AB, ELIMIT Investigators et al (2011) Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. J Vasc Surg 53:668-675
25. Linnemann B, Prochnow S, Mani H, Schwonberg J, Lindhoff-Last E (2009) Variability of non-response to aspirin in patients with peripheral arterial occlusive disease during long-term follow-up. Ann Hematol 88:979-988
26. Van der Loo B, Braun J, Koppensteiner R (2011) On-treatment function testing of platelets and long-term outcome of patients with peripheral arterial disease undergoing transluminal angioplasty. Eur J Vasc Endovasc Surg 42:809-816
27. Elsayed S, Shavelle DM, Matthews RV, Clavijo LC (2012) "Resistance" or high on-treatment platelet reactivity to aspirin and clopidogrel in patients with critical limb ischemia. J Am Coll Cardiol 59(13):1142-1149
28. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106
29. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 13:349-360
30. Hamm C, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, ESC Committee for Practice Guidelines et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology. Eur Heart J 32:2999-3054
31. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 33:2569-2619
32. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G et al (2001) Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502 (Pubitemid 32758501)
33. Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al., American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups (2007) Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38:1655-1711 (Pubitemid 46691097)
34. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Twoyear follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res 71:397-403
35. Buchanan MR, Brister SJ (1995) Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 11:221-227
36. Pappas JM, Wistengard JC, Bull BS (1994) Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch Pathol Lab Med 118:801-804 (Pubitemid 24249116)
37. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235 (Pubitemid 32721947)
38. Gum PA, Kottke-Marchant K, Welsh PA, Gurm H, Welsh PA, Brooks L et al (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965 (Pubitemid 36315537)
39. Chen WP, Lee PY, Ng W, Tse HF, Lau CP (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43:1122-1126 (Pubitemid 38353000)
40. Patriginani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366-1372 (Pubitemid 12081064)
41. Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V et al (1983) Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 308:800-805 (Pubitemid 13114674)
42. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M et al (2001) Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119:39S-63S (Pubitemid 32154194)
43. Awtry EH, Loscalzo J (2000) Aspirin. Circulation 101:1206-1218 (Pubitemid 30146625)
44. Cipollone F, Rocca B, Patrono C (2004) Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 24:246-255 (Pubitemid 38197575)
45. Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ et al (2001) Prevention of inflammation-induced endothelial dysfunction: a novel vasculoprotective action of aspirin. Circulation 105:2600-2604 (Pubitemid 34596035)
46. Damas JK, Waehre T, Yndestad A, Otterdal K, Hognestad A, Solum NO et al (2003) Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation 107:2670-2676 (Pubitemid 36667239)
47. Michelson AD (2009) Methods for the measurement of platelet function. Am J Cardiol 103(Suppl):20A-26A
48. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W (2000) Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyser PFA-100. Thromb Haemost 82:316-321 (Pubitemid 30093238)
49. Wang JC, Aucoin-Barry D, Manuelian D, Monbouquette R, Reisman M, Gray W et al (2003) Incidence of aspirin nonresponsiveness using the Ultegra rapid platelet function assay- ASA. Am J Cardiol 92:1492-1494 (Pubitemid 37532584)
50. Freedman JE (2003) CD40-CD40L and platelet function: beyond hemostasis. Circ Res 92:944-946
51. Mehta J, Mehta P, Burger C, Pepine CJ (1978) Platelet aggregation studies in coronary artery disease. Part 4.Effect of aspirin. Atherosclerosis 31:169-175 (Pubitemid 9042840)
52. Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J et al (1997) A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 44:151-155 (Pubitemid 27327067)
53. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G et al (2002) Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 107:45-49 (Pubitemid 35284424)
54. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL et al (1994) Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25:2331-2336 (Pubitemid 24359298)
55. Grundmann KJK, Kleine B, Dichgans J, Dichgans J, Topka H (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250:63-66 (Pubitemid 36206686)
56. Grotemeyer KH (1991) Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb Res 63:587-593
57. Andersen K, Hurlen M, Arnesen H, Seljeflot I (2002) Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 108:37-42 (Pubitemid 36197660)
58. Zimmerman N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E et al (2003) Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108:542-547 (Pubitemid 36961167)
59. Hung J, Lam JYT, Lacoste L, Letchacovski G (1995) Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 92:2432-2436
60. Brockmann MA, Beythien C, Magens MM, Wilckens V, Kuehnl P, Gutensohn K (2001) Platelet hemostasis capacity in smokers. In vitro function analyses with 3.2% citrated blood. Thromb Res 104:333-342 (Pubitemid 33152954)
61. Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O et al (2004) Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 147:293-300 (Pubitemid 38176831)
62. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809-1817
63. Kurth T, Glynn RJ, Walker AM, Chan KA, Buring JE, Hennekens CH et al (2003) Inhibition of clinical benefits of aspirin on first myocardial infarction by non-steroidal anti-inflammatory drugs. Circulation 108:1191-1195 (Pubitemid 37099986)
64. Maclouf J, Folco G, Patrono C (1998) Eicosanoids and isoeicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 79:691-705 (Pubitemid 28163838)
65. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd (1990) A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87: 9383-9387 (Pubitemid 120030630)
66. Valles J, Santos MT, Aznar J, Osa A, Lago A, Cosin J et al (1998) Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 97:350-355 (Pubitemid 28074335)
67. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS (2003) Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med 163:1145-1153 (Pubitemid 36613066)
68. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A (2001) Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104:2666-2672 (Pubitemid 33108131)
69. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C et al (2000) Platelet GP IIIaPl(A) polymorphisms display different sensitivities to agonists. Circulation 101:1013-1018 (Pubitemid 30131704)
70. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives. J Am Coll Cardiol 49:1505-1516 (Pubitemid 46517957)
71. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV (2007) Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 154:221-231 (Pubitemid 47069129)
72. Geisler T, Zurn C, Simonenko R, Rapin M, Kraibooj H, Kilias A et al (2010) Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 31:59-66
73. Kassimis G, Stavrou EF, Alexopoulos D, Athanassiadou A (2013) Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped? Curr Pharm Des 19:2489-2495
74. Tousoulis D, Siasos G, Zaromitidou M, Papageorgiou N, Stefanadi E, Oikonomou E et al (2011) The role of the cytochrome P450 polymorphism in clopidogrel efficacy and clinical utility. Curr Med Chem 18:427-438
75. Serebruany V, Cherala G, Williams C, Surigin S, Booze C, Kuliczkowski W et al (2009) Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of "resistance.". Am Heart J 158:925-932
76. Siasos G, Tousoulis D, Stefanadis C (2009) Multiple mechanisms affect the clopidogrel response. J Am Coll Cardiol 53:900-901
77. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430-2435 (Pubitemid 41134272)
78. Alexopoulos D, Panagiotou A, Xanthopoulou I, Komninakis D, Kassimis G, Davlouros P et al (2011) Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost 9:2379-2385
79. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramírez C, Sabaté M, Fernandez C et al (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16:169-174 (Pubitemid 38456448)
80. Breet N, Sluman M, van Berkel M, van Werkum JW, Bouman HJ, Harmsze AM et al (2011) Effect of gender difference on platelet reactivity. Neth Heart J 19:451-457
81. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS (2009) Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 103:1339-1343
82. Geisler T, Kapp M, Gohring-Frischholz K, Daub K, Dösch C, Bigalke B et al (2008) Residual platelet activity is increased in clopidogrel and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 94:743-747 (Pubitemid 351744692)
83. Osmancik P, Jirmar R, Hulikova K, Peroutka Z, Pompachova A, Motovska Z et al (2010) A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction. Catheter Cardiovasc Interv 75:158-166
84. Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J et al (2010) Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. J Thromb Haemost 104:1193-1200
85. Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA et al (2008) The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 52:531-533
86. Hochholzer W, Trenk D, Mega JL, Morath T, Stratz C, Valina CM et al (2011) Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. Am Heart J 162(518-526):e5
87. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, CHARISMA Investigators et al (2009) Smoking, clopidogrel and mortality in patients with established cardiovascular disease. Circulation 120:2337-2344
88. Desai NR, Mega JL, Jiang S, Cannon CP, Sabatine MS (2009) Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 53:1273-1278
89. Ueno M, Ferreiro JL, Desai B, Tomasello SD, Tello-Montoliu A, Capodanno D et al (2012) Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. JACC Cardiovasc Interv 5:293-300
90. Sibbing D, Morath T, Stegherr J, Braun S, Vogt W, Hadamitzky M et al (2009) Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. J Thromb Haemost 101:714-719
91. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, COGENT Investigators et al (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363:1909-1917
92. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS et al (2003) Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107:32-37 (Pubitemid 36070929)
93. Harmsze AM, Robijns K, van Werkum JW, Breet NJ, Hackeng CM, Ten Berg JM et al (2010) The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers, is associated with clopidogrel poor-response. J Thromb Haemost 103: 920-925
94. Siller-Matula JM, Lang I, Christ G, Jilma B (2008) Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52:1557-1563
95. Sibbing D, Von Beckerath N, Morath T, Stegherr J, Mehilli J, Sarafoff N et al (2010) Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J 31:1205-1211
96. Sarafoff N, Ndrepepa G, Mehilli J, Dörrler K, Schulz S, Iijima R et al (2008) Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 264:472-480
97. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T et al (2010) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376:1312-1319
98. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354-362
99. Rudez G, Bouman HJ, van Werkum JW, Leebeek FW, Kruit A, Ruven HJ et al (2009) Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2:515-521
100. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T et al (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486-501 (Pubitemid 44767878)
101. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C et al (2006) Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247 (Pubitemid 44497506)
102. Desta Z, Zhao X, Shin J-G, Flockhart DA (2002) Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacokinet 41:913-958 (Pubitemid 35168437)
103. Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF et al (2011) Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 4:403-410
104. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM et al (2008) Cytochrome P450 2 C19 681GNA polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925-1934 (Pubitemid 351636443)
105. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K et al (2010) Reduced function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304:1821-1830
106. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J et al (2009) Cytochrome P450 2 C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309-317
107. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K et al (2009) Cytochrome P450 2 C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30:916-922
108. Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927-929
109. Dahlen JR, Price MJ, Parise H, Gurbel PA (2012) Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. Thromb Haemost 109(5):808-816
110. Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD et al (2012) Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 22(9):1998-2006
111. Pastromas G, Spiliopoulos S, Katsanos K, Diamantopoulos A, Kitrou P, Karnabatidis D, et al. (2013, February 14) Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol [Epub ahead of print]
112. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12): 919-933
113. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D (2013) Platelet REsponsiveness to CLOpidogrel treatment after Peripheral endovascular procedures - The PRECLOP study: Clinical impact and optimal cut-off value of high on treatment platelet reactivity. J Am Coll Cardiol 61(24): 2428-2434
114. Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E et al (2012) Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 59(6):777-785
115. Hall HM, Banerjee S, McGuire DK (2011) Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 8(4):245-253
116. Rho GJ, Shin WR, Kong TS, Kim MS, Lee CJ, Lee BH (2011) Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. J Korean Neurosurg Soc 50(1):40-44
117. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK (2008) Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 29(2):281-285 (Pubitemid 351287881)
118. Kliger C, Babaev A, Shah B, et al. (2012) Dual antiplatelet therapy responsiveness in patients undergoing percutaneous revascularization for peripheral arterial occlusive disease. Presented at ACC, Chicago, IL, March 24-27
119. Wiviott S, Braunwald E, McCabe C, Montalescot G, Ruzyllo W, Gottlieb S, TRITON-TIMI 38 Investigators et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015 (Pubitemid 350106708)
120. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057
121. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, et al ARCTIC Investigators (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 29:367(22):2100-2109
122. Paraskevopoulos I, Spiliopoulos S, Davlouros P, Karnabatidis D, Katsanos K, Alexopoulos D et al (2013) Evaluation of below-the-knee drug-eluting stents with frequency-domain optical coherence tomography: neointimal hyperplasia and neoatherosclerosis. J Endovasc Ther 20(1):80-93
123. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y (2012) In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol 59:2051-2057
124. Liang Y, Johnston M, Hirsh J, Pare G, Li C, Mehta S, Teo KK et al (2010) Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin. J Thromb Thrombolysis 34(4):429-436
125. Chassot PG, Marcucci C, Delabays A, Spahn DR (2010) Perioperative antiplatelet therapy. Am Fam Phys 82(12):1484-1489